Loader
research-image

Research & Clinical Trials

In Raffles Cancer Centre, we actively seek partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients. Clinical trials constitute an integral component of patient management in Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet made available in the market,  will give hope even after their conditions have failed to respond to standard lines of treatment.

Our specialists in Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.

Coordinated by the Hospital ‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.

All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well –being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.

No.

Indication

Study Information

Investigator

Status

1

Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

 

Dr Daryl Tan

Recruiting

2

Thrombotic Microangiopathies

Atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), or hematopoietic stem cell transplant (HSCT)-associated TMA

 

Dr Daryl Tan

Recruiting

4

Colorectal Cancer

Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

 

Dr Donald Poon

Recruiting

5

B-cell lymphoma

Transplant-eligible relapsed/refractory diffuse large B-cell lymphoma in patients not achieving a complete response at pre-transplant interim assessment

 

Dr Daryl Tan

Recruiting

6

Non-Hodgkin’s lymphoma (iNHL)

Relapsed indolent Non-Hodgkin’s lymphoma, after 1-3 lines of treatment

Dr Daryl Tan

Recruiting

7

Gastric Cancer

Maintainence Therapy in patients with Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

Dr Lynette Ngo

Recruiting

8

NPC

Immunotherapy Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

Dr Chin Tan Min

Recruiting

9

Ovarian Cancer

Immunotherapy in Combination with Chemotherapy followed by maintenance therapy in patients with previously untreated advanced ovarian cancer

 

Dr Lynette Ngo

Recruiting

10

Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Dr Daryl Tan

Upcoming

11

Breast Cancer

A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer

 

Dr Lynette Ngo

Upcoming

12

Acute Lymphoblastic Leukemia

Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Eligible for Hematopoietic Stem Cell Transplantation and who have Risk Factor(s) for Veno-Occlusive Disease

 

Dr Yvonne Loh

Upcoming

13

Stem Cell Transplant

Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Dr Yvonne Loh

Upcoming

For more information, please contact:

Raffles Hospital Clinical Trials Unit
Mon - Fri: 9.00am to 5.00pm
Tel: +65 6311 2305
Emailyang_christie@rafflesmedical.com

Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.

Update Feb 2019